The global venture capital landscape in 2025 and 2026 has witnessed a pronounced polarization. While macroeconomic pressures have forced a sharp reset in capital intensity for early-stage health technology startups, later-stage funding has increasingly concentrated in a select group of heavily capitalised, vertically integrated platforms. This trend culminated in the announcement that Stockholm-based preventative diagnostics firm Neko Health raised $700 million in a Series C